Suggested remit: To appraise the clinical and cost effectiveness of dupilumab within its marketing authorisation for treating prurigo nodularis.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 4054

Provisional Schedule

Expected publication 13 March 2024

Project Team

Project lead Vonda Murray

Email enquiries

External Assessment Group Centre for Reviews and Dissemination and Centre for Health Economics, University of York

Stakeholders

Companies sponsors Sanofi (dupilumab)
Others Department of Health and Social Care
  NHS England
  Welsh Government
Patient carer groups Prurigo Nodularis International
Professional groups British Association of Dermatologists
  Royal College of Physicians
Assessment group Centre for Reviews and Dissemination and Centre for Health Economics – York
Comparator companies Accord (cetirizine hydrochloride, citalopram, escitalopram, desloratadine, duloxetine, fluoxetine, loratadine, methotrexate, paroxetine, sertraline, thalidomide, venlafaxine) (confidentiality agreement not signed, not participating)
  ADVANZ Pharma (citalopram, fluoxetine, methotrexate, venlafaxine) (confidentiality agreement not signed, not participating)
  Aspen (azathioprine) (confidentiality agreement not signed, not participating)
  Amarox (citalopram, duloxetine) (confidentiality agreement not signed, not participating)
  A.Menarini Farmaceutica (confidentiality agreement not signed, not participating)
  Internazionale (bilastine, dapoxetine) (confidentiality agreement not signed, not participating)
  Aspire Pharma (duloxetine, rupatadine, venlafaxine) (confidentiality agreement not signed, not participating)
  Aurobindo Pharma-Milpharm (cetirizine hydrochloride, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline, venlafaxine) (confidentiality agreement not signed, not participating)
  Bayer (loratadine) (confidentiality agreement not signed, not participating)
  Bristol Myers Squibb (cetirizine hydrochloride, thalidomide, venlafaxine) (confidentiality agreement not signed, not participating)
  Brown & Burk (acrivastine, escitalopram, fluoxetine, levocetirizine hydrochloride, loratadine) (confidentiality agreement not signed, not participating)
  Cipla EU (cetirizine hydrochloride, fexofenadine hydrochloride, fluoxetine, methotrexate) (confidentiality agreement not signed, not participating)
  Dexcel Pharma (cetirizine hydrochloride, ciclosporin, venlafaxine) (confidentiality agreement not signed, not participating)
  Dr. Reddy’s Laboratories (cetirizine hydrochloride, duloxetine, fexofenadine hydrochloride, fluoxetine, sertraline) (confidentiality agreement not signed, not participating)
  Eli Lily and Company (duloxetine) (confidentiality agreement not signed, not participating)
  Endo Ventures (fluoxetine) (confidentiality agreement not signed, not participating)
  Fannin / Kent Pharma (fexofenadine hydrochloride, fluoxetine) (confidentiality agreement not signed, not participating)
  Flamingo Pharma (fluoxetine, sertraline) (confidentiality agreement not signed, not participating)
  GlaxoSmithKline (bupropion hydrochloride, cetirizine hydrochloride, paroxetine) (confidentiality agreement not signed, not participating)
  Glenmark Pharmaceuticals Europe (desloratadine, escitalopram, levocetirizine hydrochloride) (confidentiality agreement not signed, not participating)
  Hospira (methotrexate) (confidentiality agreement not signed, not participating)
  Lundbeck (citalopram, escitalopram, vortioxetine) (confidentiality agreement not signed, not participating)
  Lupin Healthcare (sertraline) (confidentiality agreement not signed, not participating)
  Martindale Pharma (venlafaxine) (confidentiality agreement not signed, not participating)
  medac GmbH (methotrexate) (confidentiality agreement not signed, not participating)
  McNeil Products (acrivastine, (confidentiality agreement not signed, not participating) cetirizine hydrochloride)
  Morningside Healthcare (methotrexate, paroxetine, venlafaxine) (confidentiality agreement not signed, not participating)
  Mylan (azathioprine, ciclosporin, desloratadine, fluvoxamine, levocetirizine hydrochloride, sertraline) (confidentiality agreement not signed, not participating)
  Neuraxpharm (duloxetine) (confidentiality agreement not signed, not participating)
  Nordic Pharma (methotrexate) (confidentiality agreement not signed, not participating)
  Nova Laboratories (azathioprine) (confidentiality agreement not signed, not participating)
  Novartis (ciclosporin) (confidentiality agreement not signed, not participating)
  Orexigen Therapeutics Ireland (bupropion hydrochloride) (confidentiality agreement not signed, not participating)
  Organon Pharma (desloratadine) (confidentiality agreement not signed, not participating)
  Orion (methotrexate) (confidentiality agreement not signed, not participating)
  Pfizer (methotrexate) (confidentiality agreement not signed, not participating)
  Pinewood (cetirizine hydrochloride, fluoxetine, loratadine) (confidentiality agreement not signed, not participating)
  Ranbaxy (loratadine, sertraline, venlafaxine) (confidentiality agreement not signed, not participating)
  Rivopharm (citalopram) (confidentiality agreement not signed, not participating)
  Rosemont Pharmaceuticals (fluoxetine, methotrexate, venlafaxine) (confidentiality agreement not signed, not participating)
  Sandoz (citalopram, methotrexate, paroxetine) (confidentiality agreement not signed, not participating)
  Sanofi (fexofenadine hydrochloride, mizolastine) (confidentiality agreement not signed, not participating)
  Santen (ciclosporin) (confidentiality agreement not signed, not participating)
  Sovereign Medical (citalopram, venlafaxine) (confidentiality agreement not signed, not participating)
  Thame Laboratories (citalopram) (confidentiality agreement not signed, not participating)
  The Boots Company (cetirizine hydrochloride, loratadine) (confidentiality agreement not signed, not participating)
  Therakind (methotrexate) (confidentiality agreement not signed, not participating)
  Tillomed Laboratories (azathioprine, duloxetine) (confidentiality agreement not signed, not participating)
  UCB Pharma (cetirizine hydrochloride, levocetirizine hydrochloride) (confidentiality agreement not signed, not participating)
  Upjohn (sertraline, venlafaxine) (confidentiality agreement not signed, not participating)
  Wockhardt (cetirizine hydrochloride) (confidentiality agreement not signed, not participating)
  Zentiva (citalopram, duloxetine, fexofenadine hydrochloride, sertraline) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Health Specialised Services Committee

Timeline

Key events during the development of the guidance:

Date Update
08 February 2024 - 22 February 2024 Final draft guidance
04 October 2023 Committee meeting: 2
23 August 2023 - 14 September 2023 Draft guidance
02 August 2023 Committee meeting: 1
24 November 2022 Invitation to participate
17 August 2022 (14:00) Scoping workshop
06 July 2022 - 03 August 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
06 July 2022 In progress

For further information on our processes and methods, please see our CHTE processes and methods manual